IL115420A0
(en)
|
1994-09-26 |
1995-12-31 |
Zeneca Ltd |
Aminoheterocyclic derivatives
|
GB9516709D0
(en)
*
|
1995-08-15 |
1995-10-18 |
Zeneca Ltd |
Medicament
|
US6083949A
(en)
*
|
1995-10-06 |
2000-07-04 |
Merck & Co., Inc. |
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
|
US6313127B1
(en)
|
1996-02-02 |
2001-11-06 |
Zeneca Limited |
Heterocyclic compounds useful as pharmaceutical agents
|
GB9602166D0
(en)
|
1996-02-02 |
1996-04-03 |
Zeneca Ltd |
Aminoheterocyclic derivatives
|
JP2001518067A
(en)
*
|
1996-04-03 |
2001-10-09 |
メルク エンド カンパニー インコーポレーテッド |
Inhibitors of farnesyl protein transferase
|
WO1997038665A2
(en)
*
|
1996-04-03 |
1997-10-23 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
JP2000507589A
(en)
*
|
1996-04-03 |
2000-06-20 |
メルク エンド カンパニー インコーポレーテッド |
Farnesyl-protein transferase inhibitor
|
AU707139B2
(en)
*
|
1996-04-03 |
1999-07-01 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5939557A
(en)
*
|
1996-04-03 |
1999-08-17 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
WO1997036892A1
(en)
*
|
1996-04-03 |
1997-10-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5965578A
(en)
*
|
1996-04-03 |
1999-10-12 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5922883A
(en)
*
|
1996-04-03 |
1999-07-13 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5869682A
(en)
*
|
1996-04-03 |
1999-02-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5925651A
(en)
*
|
1996-04-03 |
1999-07-20 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5780488A
(en)
*
|
1996-04-03 |
1998-07-14 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5874452A
(en)
*
|
1996-04-03 |
1999-02-23 |
Merck & Co., Inc. |
Biheteroaryl inhibitors of farnesyl-protein transferase
|
US5885995A
(en)
*
|
1996-04-03 |
1999-03-23 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6001835A
(en)
*
|
1996-04-03 |
1999-12-14 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5780492A
(en)
*
|
1996-04-03 |
1998-07-14 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
CA2250232A1
(en)
*
|
1996-04-03 |
1997-10-09 |
Allen I. Oliff |
A method of treating cancer
|
US5891889A
(en)
*
|
1996-04-03 |
1999-04-06 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
CA2250143A1
(en)
*
|
1996-04-03 |
1997-10-09 |
Jeffrey Bergman |
Inhibitors of farnesyl-protein transferase
|
US5919785A
(en)
*
|
1996-04-03 |
1999-07-06 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5852010A
(en)
*
|
1996-04-03 |
1998-12-22 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6080870A
(en)
*
|
1996-04-03 |
2000-06-27 |
Merck & Co., Inc. |
Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
|
US6063930A
(en)
*
|
1996-04-03 |
2000-05-16 |
Merck & Co., Inc. |
Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
|
US5859012A
(en)
*
|
1996-04-03 |
1999-01-12 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5883105A
(en)
*
|
1996-04-03 |
1999-03-16 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6093718A
(en)
*
|
1996-08-14 |
2000-07-25 |
Zeneca Limited |
Substituted pyrimidine derivatives and their pharmaceutical use
|
UA56197C2
(en)
|
1996-11-08 |
2003-05-15 |
Зенека Лімітед |
Heterocyclic derivatives
|
CA2276081A1
(en)
*
|
1996-12-30 |
1998-07-09 |
Lekhanh O. Tran |
Inhibitors of farnesyl-protein transferase
|
US6391880B1
(en)
|
1997-02-13 |
2002-05-21 |
Zeneca Limited |
Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
|
US6440972B1
(en)
|
1997-02-13 |
2002-08-27 |
Zeneca Limited |
Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
|
US5972942A
(en)
*
|
1997-03-27 |
1999-10-26 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6060038A
(en)
*
|
1997-05-15 |
2000-05-09 |
Merck & Co., Inc. |
Radiolabeled farnesyl-protein transferase inhibitors
|
AUPO735997A0
(en)
|
1997-06-17 |
1997-07-10 |
Fujisawa Pharmaceutical Co., Ltd. |
Piperazine derivatives
|
GB9715895D0
(en)
|
1997-07-29 |
1997-10-01 |
Zeneca Ltd |
Heterocyclic compounds
|
CA2301880A1
(en)
*
|
1997-08-27 |
1999-03-04 |
Merck & Co., Inc. |
A method of treating cancer
|
US6103487A
(en)
*
|
1997-08-27 |
2000-08-15 |
Merck & Co., Inc. |
Method of treating cancer
|
US6387903B1
(en)
|
1997-08-27 |
2002-05-14 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
FR2774985A1
(en)
*
|
1998-02-13 |
1999-08-20 |
Rhone Poulenc Rorer Sa |
New naphthyl carbonyl or sulfonyl oxopiperazine farnesyl transferase inhibitors, used as antiproliferative agents, e.g. for treating cancer
|
AU2286099A
(en)
*
|
1998-02-13 |
1999-08-30 |
Rhone-Poulenc Rorer S.A. |
Di-substituted naphthyl derivatives, preparation thereof, pharmaceutical compositions containing them
|
AU5086499A
(en)
*
|
1998-07-01 |
2000-01-24 |
Merck & Co., Inc. |
Process for making farnesyl-protein transferase inhibitors
|
GB9902989D0
(en)
|
1999-02-11 |
1999-03-31 |
Zeneca Ltd |
Heterocyclic derivatives
|
WO2000052134A2
(en)
*
|
1999-03-03 |
2000-09-08 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
CA2362778A1
(en)
*
|
1999-03-03 |
2000-09-08 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
CA2362493A1
(en)
*
|
1999-03-03 |
2000-09-08 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
EP1158983A4
(en)
*
|
1999-03-03 |
2003-05-21 |
Merck & Co Inc |
Inhibitors of prenyl-protein transferase
|
US6211182B1
(en)
*
|
1999-03-08 |
2001-04-03 |
Schering Corporation |
Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
|
US6458935B1
(en)
|
1999-06-23 |
2002-10-01 |
Merck & Co., Inc. |
Radiolabeled farnesyl-protein transferase inhibitors
|
FR2819510B1
(en)
*
|
2001-01-18 |
2003-10-31 |
Servier Lab |
NOVEL CYCLO [C] AZEPANE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
|
FR2819509B1
(en)
*
|
2001-01-18 |
2004-04-16 |
Servier Lab |
NOVEL CYCLOHEPTENE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
FR2819512B1
(en)
*
|
2001-01-18 |
2003-02-21 |
Servier Lab |
NOVEL CYCLO [D] AZEPANE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
ATE550019T1
(en)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
CIS-4-Ä(4-CHLOROPHENYL)SULFONYLÜ-4-(2,5-DIFLUOROPHENYL)CYCLOHEXANEPROPANE ACID FOR THE TREATMENT OF CANCER
|
RS51470B
(en)
|
2005-09-16 |
2011-04-30 |
Arrow Therapeutics Limited |
Biphenyl derivatives and their use in treating hepatitis c
|
WO2007070514A1
(en)
|
2005-12-13 |
2007-06-21 |
Incyte Corporation |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
EP2083831B1
(en)
|
2006-09-22 |
2013-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
WO2008076336A2
(en)
*
|
2006-12-18 |
2008-06-26 |
Novartis Ag |
Imidazoles as aldosterone synthase inhibitors
|
JP4611444B2
(en)
|
2007-01-10 |
2011-01-12 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
Amide substituted indazoles as poly (ADP-ribose) polymerase (PARP) inhibitors
|
JP5330274B2
(en)
|
2007-03-01 |
2013-10-30 |
ノバルティス アーゲー |
PIM kinase inhibitor and method of use thereof
|
EP2152700B1
(en)
|
2007-05-21 |
2013-12-11 |
Novartis AG |
Csf-1r inhibitors, compositions, and methods of use
|
RS58449B1
(en)
|
2007-06-13 |
2019-04-30 |
Incyte Holdings Corp |
Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
US7982071B2
(en)
|
2007-10-05 |
2011-07-19 |
Acucela Inc. |
Alkoxy compounds for disease treatment
|
EP2110374A1
(en)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
|
GB0813142D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
GB0813144D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
US20120121515A1
(en)
|
2009-03-13 |
2012-05-17 |
Lenny Dang |
Methods and compositions for cell-proliferation-related disorders
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
AU2010234526B2
(en)
|
2009-04-06 |
2016-07-21 |
Agios Pharmaceuticals, Inc. |
Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use
|
EP3643312A1
(en)
|
2009-05-22 |
2020-04-29 |
Incyte Holdings Corporation |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
AU2010249380B2
(en)
|
2009-05-22 |
2015-08-20 |
Incyte Holdings Corporation |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
|
JP6073677B2
(en)
|
2009-06-12 |
2017-02-01 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Fused heterocyclic compounds and their use
|
TWI691493B
(en)
|
2009-06-29 |
2020-04-21 |
美商阿吉歐斯製藥公司 |
Therapeutic compounds and compositions
|
US10471027B2
(en)
|
2009-07-02 |
2019-11-12 |
Acucela, Inc. |
Pharmacology of visual cycle modulators
|
AR078012A1
(en)
|
2009-09-01 |
2011-10-05 |
Incyte Corp |
HETEROCICLIC DERIVATIVES OF PIRAZOL-4-IL-PIRROLO (2,3-D) PYRIMIDINS AS INHIBITORS OF THE QUANASA JANUS
|
CN102638981B
(en)
|
2009-10-14 |
2015-07-22 |
默沙东公司 |
Substituted piperidines that increase p53 activity and the uses thereof
|
EP2491145B1
(en)
|
2009-10-21 |
2016-03-09 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
EP2937345B1
(en)
|
2009-12-29 |
2018-03-21 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
CN102985417B
(en)
|
2010-03-10 |
2015-01-28 |
因塞特公司 |
Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
|
WO2011115725A2
(en)
|
2010-03-16 |
2011-09-22 |
Dana-Farber Cancer Institute, Inc. |
Indazole compounds and their uses
|
EA035981B1
(en)
|
2010-05-21 |
2020-09-09 |
Инсайт Холдингс Корпорейшн |
Jak inhibitor formulation for topical application
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
CA2805265A1
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
EP2606134B1
(en)
|
2010-08-17 |
2019-04-10 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
EP2632472B1
(en)
|
2010-10-29 |
2017-12-13 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
EP2640725B1
(en)
|
2010-11-19 |
2015-01-07 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
|
TW201249845A
(en)
|
2010-11-19 |
2012-12-16 |
Incyte Corp |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
EP2651898B1
(en)
|
2010-12-17 |
2015-12-09 |
Agios Pharmaceuticals, Inc. |
Novel n-(4-(azetidine-1-carbonyl)phenyl)-(hetero-)arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators
|
EP2655350B1
(en)
|
2010-12-21 |
2016-03-09 |
Agios Pharmaceuticals, Inc. |
Bicyclic pkm2 activators
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
TWI549947B
(en)
|
2010-12-29 |
2016-09-21 |
阿吉歐斯製藥公司 |
Therapeutic compounds and compositions
|
JP2014514321A
(en)
|
2011-04-21 |
2014-06-19 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Insulin-like growth factor 1 receptor inhibitor
|
CN103608016A
(en)
|
2011-05-03 |
2014-02-26 |
安吉奥斯医药品有限公司 |
Pyruvate kinase activators for use in therapy
|
ME03074B
(en)
|
2011-05-03 |
2019-01-20 |
Agios Pharmaceuticals Inc |
Pyruvate kinase activators for use in therapy
|
CN102827073A
(en)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
Therapeutically active compositions and application methods thereof
|
CN102827170A
(en)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
Active treatment compositions and use method thereof
|
WO2012177606A1
(en)
|
2011-06-20 |
2012-12-27 |
Incyte Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
TW201313721A
(en)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
Cyclohexyl azetidine derivatives as JAK inhibitors
|
UA111854C2
(en)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
WO2013074986A1
(en)
|
2011-11-17 |
2013-05-23 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
US9474779B2
(en)
|
2012-01-19 |
2016-10-25 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compositions and their methods of use
|
JP6399660B2
(en)
*
|
2012-04-10 |
2018-10-03 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
Cancer treatment compositions and methods
|
EP3453762B1
(en)
|
2012-05-02 |
2021-04-21 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
TW201406761A
(en)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
US9233979B2
(en)
|
2012-09-28 |
2016-01-12 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
WO2014063068A1
(en)
|
2012-10-18 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
US9758522B2
(en)
|
2012-10-19 |
2017-09-12 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
US10000483B2
(en)
|
2012-10-19 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
|
CN113384545A
(en)
|
2012-11-15 |
2021-09-14 |
因赛特公司 |
Sustained release dosage forms of ruxolitinib
|
RU2660349C2
(en)
|
2012-11-28 |
2018-07-05 |
Мерк Шарп И Доум Корп. |
Compositions and methods for treatment of malignant tumour
|
BR112015013611A2
(en)
|
2012-12-20 |
2017-11-14 |
Merck Sharp & Dohme |
compound and pharmaceutical composition
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
SI3489239T1
(en)
|
2013-03-06 |
2022-04-29 |
Incyte Holdings Corporation |
Processes and intermediates for making a jak inhibitor
|
EP3587406B1
(en)
|
2013-03-13 |
2021-01-27 |
Forma Therapeutics, Inc. |
2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer
|
WO2015003360A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
WO2015003355A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
CA2917671A1
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
|
US9579324B2
(en)
|
2013-07-11 |
2017-02-28 |
Agios Pharmaceuticals, Inc |
Therapeutically active compounds and their methods of use
|
US20150031627A1
(en)
|
2013-07-25 |
2015-01-29 |
Agios Pharmaceuticals, Inc |
Therapeutically active compounds and their methods of use
|
EA201690357A1
(en)
|
2013-08-07 |
2016-07-29 |
Инсайт Корпорейшн |
DOSAGE FORMS WITH Slow Release For JAK1 Inhibitor
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
CA2927917C
(en)
|
2013-10-18 |
2022-08-09 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of proliferative diseases
|
AU2014337044A1
(en)
|
2013-10-18 |
2016-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
AU2015229214B2
(en)
|
2014-03-14 |
2019-07-11 |
Les Laboratoires Servier |
Pharmaceutical compositions of therapeutically active compounds
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
US9862688B2
(en)
|
2014-04-23 |
2018-01-09 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
JO3589B1
(en)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
Protein kinase c inhibitors and methods of their use
|
KR102134171B1
(en)
|
2014-10-24 |
2020-07-15 |
란도스 바이오파마, 인크. |
Lanthionine synthetase c-like 2-based therapeutics
|
WO2016105528A2
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
AU2016243529B2
(en)
|
2015-03-27 |
2021-03-25 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
EP4344703A1
(en)
|
2015-06-11 |
2024-04-03 |
Agios Pharmaceuticals, Inc. |
Methods of using pyruvate kinase activators
|
US10702527B2
(en)
|
2015-06-12 |
2020-07-07 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
AU2016319125B2
(en)
|
2015-09-09 |
2021-04-08 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
EP3362065B1
(en)
|
2015-10-15 |
2024-04-03 |
Les Laboratoires Servier |
Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia
|
PT3362066T
(en)
|
2015-10-15 |
2021-11-16 |
Celgene Corp |
Combination therapy for treating malignancies
|
JOP20190055A1
(en)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
Anti-cd27 antibodies
|
KR20190140454A
(en)
|
2017-04-13 |
2019-12-19 |
아두로 바이오테크 홀딩스, 유럽 비.브이. |
Anti-SIRP alpha antibody
|
PL3641769T3
(en)
|
2017-06-20 |
2022-09-26 |
Imbria Pharmaceuticals, Inc. |
1-[(2,3,4-trimethoxyphenyl)methyl]-piperazine derivative, compositions thereof and methods for increasing efficiency of cardiac metabolism
|
EP3706742B1
(en)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
SI3746429T1
(en)
|
2018-01-30 |
2023-01-31 |
Incyte Corporation |
Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
CN110294713B
(en)
*
|
2018-03-22 |
2022-08-02 |
西华大学 |
Preparation method of imidazole methylamine derivative
|
WO2019191684A1
(en)
|
2018-03-30 |
2019-10-03 |
Incyte Corporation |
Treatment of hidradenitis suppurativa using jak inhibitors
|
US10980788B2
(en)
|
2018-06-08 |
2021-04-20 |
Agios Pharmaceuticals, Inc. |
Therapy for treating malignancies
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
TWI767148B
(en)
|
2018-10-10 |
2022-06-11 |
美商弗瑪治療公司 |
Inhibiting fatty acid synthase (fasn)
|
CN113382633A
(en)
|
2018-10-29 |
2021-09-10 |
福马治疗股份有限公司 |
Solid forms of (4- (2-fluoro-4- (1-methyl-1H-benzo [ d ] imidazol-5-yl) benzoyl) piperazin-1-yl) (1-hydroxycyclopropyl) methanone
|
KR20230026522A
(en)
|
2019-12-20 |
2023-02-24 |
란도스 바이오파마, 인크. |
Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
US11530184B2
(en)
|
2020-06-30 |
2022-12-20 |
Imbria Pharmaceuticals, Inc. |
Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
US11780811B2
(en)
|
2020-06-30 |
2023-10-10 |
Imbria Pharmaceuticals, Inc. |
Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
US11883396B2
(en)
|
2021-05-03 |
2024-01-30 |
Imbria Pharmaceuticals, Inc. |
Methods of treating kidney conditions using modified forms of trimetazidine
|